← Research library

Semax and Selank inhibit enkephalin-degrading enzymes from human serum

Lab research · 2001

What was studied
Human-serum enzyme assays
Main finding
Both peptides and certain fragments inhibited peptide-degrading enzymes in laboratory assays.

Semax IC50 · 10 microM

Reported findings and study design

Human-serum enzyme assays comparing Semax, Selank and peptide-degradation inhibitors.

Population or model Human-serum enzyme assays

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Semax IC5010 microM
Selank IC5020 microM
Puromycin comparator IC5010 mM
Active fragmentsFive-amino-acid fragments inhibited degradation; three/four/six-amino-acid fragments did not

IC50 values measure enzyme inhibition in vitro, not clinical potency or dose equivalence.

Source for these results ↗ · Reviewed 2026-10-29

Study limitations and source details

Study limitations

  • Human-derived serum does not make this a patient trial.
  • Assay concentrations and enzyme effects do not establish a clinical mechanism or benefit.

Source details

Journal publication

Indexed citation and English abstract checked; full methods and risk of bias not appraised.

Sources checked

Citation

In vitroEnglish abstract

N V Kost, O Iu Sokolov, M V Gabaeva, I A Grivennikov, L A Andreeva, N F Miasoedov, A A Zozulia. Semax and Selank inhibit enkephalin-degrading enzymes from human serum Bioorg Khim. 27(3):180–183

Study source ↗ · DOI 10.1023/a:1011373002885 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards